Postresectional adjuvant intraportal chemotherapy in patients with hepatocellular carcinoma: A case-control study

Annals of Surgical Oncology

Volumn 13, Issue 10, 2006, Pages 1329-1337

  Chau, Gar Yang ^a,b   Lui, Wing Yiu ^a,b   Tsay, Shyh Haw ^a,b   Chao, Yee ^a,b   King, Kuang Liang ^a,b   Wu, Chew Wun ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Adjuvant chemotherapy; Hepatic resection; Hepatocellular carcinoma; Intraportal infusion; Tumor recurrence

Indexed keywords

CISPLATIN; DEXAMETHASONE; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; METOCLOPRAMIDE;

ADULT; ANEMIA; ARTICLE; BACKACHE; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; FEMALE; HUMAN; KIDNEY DYSFUNCTION; LIVER CELL CARCINOMA; LIVER RESECTION; LYMPH NODE METASTASIS; MALAISE; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PARESTHESIA; PATIENT SELECTION; THROMBOCYTOPENIA; UPPER ABDOMINAL PAIN; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DOXORUBICIN; FEMALE; FLUOROURACIL; HEPATECTOMY; HUMANS; INFUSIONS, INTRAVENOUS; LEUCOVORIN; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PORTAL VEIN; POSTOPERATIVE PERIOD; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 33748920561     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-006-9004-1     Document Type: Article

References (35)

1. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362:1907-17.
2. Chang CH, Chau GY, Lui WY, Tsay SH, King KL, Wu CW. Long-term results of hepatic resection for hepatocellular carcinoma originating from the noncirrhotic liver. Arch Surg 2004; 139:320-5.
3. Poon RTP, Fan ST, Wong J. Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg 2000; 232:10-24.
4. Vauthey JN, Klimstra D, Franceschi D, et al. Factors affecting long-term outcome after hepatic resection for hepatocellular carcinoma. Am J Surg 1995; 169:28-34.
5. Chau GY, Lui WY, Wu CW. Spectrum and significance of microscopic vascular invasion in hepatocellular carcinoma. Surg Oncol Clin North Am 2003; 12:25-34.
6. Ng KK, Vauthey JN, Pawlik TM, et al. Is hepatic resection for large or multinodular hepatocellular carcinoma justified? Results from a multi-institutional database. Ann Surg Oncol 2005; 12:364-73.
7. Schwartz JD, Schwartz M, Mandeli J, Sung M. Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomized clinical trials. Lancet Oncol 2002; 3:593-603.
8. Olthoff KM, Rosove MH, Shackleton CR, et al. Adjuvant chemotherapy improves survival after liver transplantation for hepatocellular carcinoma. Ann Surg 1995; 221:734-43.
9. Stone MJ, Klintmalm GBG, Polter D, et al. Neoadjuvant chemotherapy and liver transplantation for hepatocellular carcinoma: a pilot study in 20 patients. Gastroenterology 1993; 104:196-202.
10. Chen MF, Hwang TL, Jeng LB, Wang CS, Jan YY, Chen SC. Postoperative recurrence of hepatocellular carcinoma. Two hundred five consecutive patients underwent hepatic resection in 15 years. Arch Surg 1994; 129:738-42.
11. Chen WT, Chau GY, Lui WY, et al. Recurrent hepatocellular carcinoma after hepatic resection: prognostic factors and long-term outcome. Eur J Surg Oncol 2004; 30:414-20.
12. Meric F, Patt YZ, Curley SA, et al. Surgery after downstaging of unresectable hepatic tumors with intra-arterial chemotherapy. Ann Surg Oncol 2000; 7:490-5.
13. Poon RTP, Fan ST, Tsang FHF, Wong J. Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective. Ann Surg 2002; 235:466-86.
14. Izumi R, Shimizu K, Iyobe T, et al. Postoperative adjuvant hepatic arterial infusion of Lipiodol containing anticancer drugs in patients with hepatocellular carcinoma. Hepatology 1994; 20:295-301.
15. Lai ECS, Lo CM, Fan ST, Liu CL, Wong J. Postoperative adjuvant chemotherapy after curative resection of hepatocellular carcinoma. Arch Surg 1998; 133:183-8.
16. Kohno H, Nagasue N, Hayashi T, et al. Postoperative adjuvant chemotherapy after radical resection for hepatocellular carcinoma (HCC). Hepatogastroenterology 1996; 43:1405-9.
17. Tsai TJ, Chau GY, Lui WY, et al. Clinical significance of microscopic tumor venous invasion in patients with resectable hepatocellular carcinoma. Surgery 2000; 127:603-8.
18. Lui WY, Chau GY, Loong CC, et al. Hepatic segmentectomy for curative resection of primary hepatocellular carcinoma. Arch Surg 1995; 130:1090-7.
19. Lui WY, Chau GY. (1997) Operative approaches to hepatocellular carcinoma in the cirrhotic patient. In: Wanebo HJ. ed. Surgery for Gastrointestinal Cancer: A Multidisciplinary Approach Lippincott-Raven, Philadelphia, pp 533-9.
20. Chau GY, Lui WY, King KL, Wu CW. Evaluation of effect of hemihepatic vascular occlusion and the Pringle maneuver during hepatic resection for patients with hepatocellular carcinoma and impaired liver function. World J Surg 2005; 29:1374-83.
21. Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 1954; 7:462-503.
22. Greene FL, Page DL, Fleming ID, et al., eds. Liver including intrahepatic bile ducts. In: American Joint Committee on Cancer Staging Manual. 6th ed. New York: Springer, 2002; 131-44.
23. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958; 53:457-81.
24. Barnett KT, Malafa MP. Complications of hepatic artery infusion: a review of 4580 cases. Int J Gastrointest Cancer 2001; 30:147-60.
25. Labianca R, Fossati R, Zaniboni A, et al. Randomized trial of intraportal and/or systemic adjuvant chemotherapy in patients with colon carcinoma. J Natl Cancer Inst 2004; 96:750-8.
26. Taylor I, Machin D, Mullee ME, Trotter G, Cooke T, West C. A randomized controlled trial of adjuvant portal vein cytotoxic perfusion in colorectal cancer. Br J Surg 1985; 72:359-63.
27. Wolmark N, Rockette H, Wickerham DL, et al. Adjuvant therapy of Dukes' A, B, and C adenocarcinoma of the colon with portal-vein fluorouracil hepatic infusion: preliminary results of National Surgical Adjuvant Breast and Bowel Project C-02. J Clin Oncol 1990; 8:1466-75.
28. Elias D, Lasser PH, Rougier PH, Nitenberg G, Theodore C, Lumbroso J. Early adjuvant intraportal chemotherapy after curative hepatectomy for colorectal liver metastases - a pilot study. Eur J Surg Oncol 1987; 13:247-50.
29. Ando E, Yamashita F, Tanaka M, Tanikawa K. A novel chemotherapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk of portal vein. Cancer 1997; 79:1890-6.
30. Leung TW, Patt YZ, Lau WY, et al. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res 1999; 5:1676-81.
31. Roayaie S, Frischer JS, Emre SH, et al. Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinoma larger than 5 centimeters. Ann Surg 2002; 235:533-9.
32. Yeo W, Lam KC, Zee B, et al. Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. Ann Oncol 2004; 15:1661-6.
33. Vento S, Cainelli F, Longhi MS. Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue. Lancet Oncol 2002; 3:333-40.
34. Vizzini GB, Luca A, Marino IR. Hepatitis B virus reactivation after a single session of transarterial chemoembolization in patients with hepatocellular carcinoma. Ann Intern Med 2003; 138:691-2.
35. Ono T, Yamanoi A, El Assal ON, Kohno H, Nagasue N. Adjuvant chemotherapy after resection of hepatocellular carcinoma causes deterioration of long-term prognosis in cirrhotic patients. Metaanalysis of three randomized controlled trials. Cancer 2001; 91:2378-85.